Drugs / Mizoribine

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT02005757 Nov 2013 → Jun 2016 rheumatoid arthritis Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 32 trials
Phase 3 NCT02256150 Nov 2014 → Mar 2019 lupus nephritis Asahi Kasei Therapeutics Corporation Completed No outcome recorded
Phase 3 NCT02257697 Nov 2014 → Nov 2018 nephrotic syndrome Asahi Kasei Therapeutics Corporation Completed No outcome recorded
Phase 42 trials
Phase 4 NCT06114953 Jan 2023 → Jan 2025 disease related to solid organ transplantation Lee's Pharmaceutical Limited Unknown No outcome recorded
Phase 4 NCT05293704 May 2022 → Dec 2023 disease related to solid organ transplantation, polyomavirus infectious disease Lee's Pharmaceutical Limited Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02373202 Background Feb 2015 → Nov 2016 rheumatoid arthritis Sanofi Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Mizoribine “The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and 50mg tid in active rheumatoid arthritis patients unsuccessfully treated with...” NCT02005757
5

NCT06114953

NCT02373202

NCT05293704

NCT02257697

NCT02256150

Known as Bredinin ChEMBL registry synonym — accepted as the source's own label CHEMBL245019
Known as Mizoribina ChEMBL registry synonym — accepted as the source's own label CHEMBL245019
Known as MZR “BACKGROUND: Mizoribine (MZR) was effective and safe for living Chinese donor kidney transplantation (LDKT) on tacrolimus-based treatment 1 year after transplantation.” PMID 31155174 Jun 2019
2

“Mizoribine (MZR) is a novel agent used in long-term immunosuppressive therapy” PMID 36990111 Jun 2023

“Drug: Mizoribine (MZR)” NCT02256150

Known as NSC-289637 ChEMBL registry synonym — accepted as the source's own label CHEMBL245019
Action Inhibit “GMP synthase [glutamine-hydrolyzing] inhibitor” CHEMBL245019
Modality Small molecule CHEMBL245019
Route Oral Oral administration” NCT02256150
Target GMPS “GMP synthase [glutamine-hydrolyzing] inhibitor” CHEMBL245019